BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

0

BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) Adoption of the BeiGene,Ltd. 2018 Employee Share Purchase Plan

On June6, 2018, at the 2018 Annual General Meeting of Shareholders (the “Annual Meeting”), the shareholders of BeiGene,Ltd. (the “Company”) approved the BeiGene,Ltd. 2018 Employee Share Purchase Plan (the “2018 ESPP”).

Initially, 3,500,000 ordinary shares of the Company are reserved for issuance under the 2018 ESPP. In addition, on January1, 2019 and each January1 thereafter through January1, 2028, the number of ordinary shares reserved and available for issuance under the 2018 ESPP will be cumulatively increased by the least of (i)5,000,000 ordinary shares, (ii)0.5% of the number of ordinary shares issued and outstanding on the immediately preceding December31, or (iii)such lesser number of ordinary shares as determined by the compensation committee of the Company’s board of directors (the “Compensation Committee”); provided that the aggregate number of ordinary shares reserved and available for issuance under the 2018 ESPP may not exceed 10% of the number of ordinary shares issued and outstanding as of the date of shareholder approval.

The 2018 ESPP allows eligible employees to purchase the Company’s ordinary shares (including in the form of American Depositary Shares (“ADSs”)) at the end of each offering period, which will generally be six months, at a 15% discount to the market price of the Company’s ordinary shares or ADSs at the beginning or the end of each offering period, whichever is lower, using funds deducted from their payroll during the offering period. Eligible employees are able to authorize payroll deductions of up to 10% of their eligible earnings, subject to applicable limitations. A detailed summary of the material features of the 2018 ESPP is set forth in the Company’s definitive proxy statement for the Annual Meeting (the “Proxy Statement”) filed with the Securities and Exchange Commission on April30, 2018. That summary and the foregoing description are qualified in their entirety by reference to the text of the 2018 ESPP, which is filed as Exhibit10.1 hereto and incorporated herein by reference.

Item 5.07Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting on June6, 2018. There were 698,942,730 ordinary shares entitled to vote at the Annual Meeting as of the record date on April20, 2018, of which approximately 495,841,346 were held in the name of Citibank, N.A., which issues Company-sponsored American Depositary Receipts evidencing ADSs, which, in turn, each represent 13 ordinary shares. Of the ordinary shares entitled to vote, 624,372,794 ordinary shares, including ordinary shares represented by ADSs, or approximately 89% of the outstanding ordinary shares on the record date, were present and voted in person or by proxy at the Annual Meeting. In accordance with the Company’s Memorandum and Articles of Association, the quorum required for a general meeting of shareholders at which an ordinary resolution has been proposed consists of such shareholders present in person or by proxy who together hold shares which carry the right to at least a simple majority of all votes capable of being exercised on a poll.

The matters set forth below were voted on at the Annual Meeting. Detailed descriptions of these matters and voting procedures applicable to these matters at the Annual Meeting are contained in the Proxy Statement. Set forth below are the total number of shares voted for and against each matter, as well as the total number of abstentions and broker non-votes with respect to each matter.

(1) Ordinary resolution: to re-elect Donald W. Glazer to serve as a ClassII director until the 2021 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal:

VotesFor

VotesAgainst

Abstentions

BrokerNon-Votes

610,012,760

14,163,370

196,664

Accordingly, Donald W. Glazer was re-elected to serve as a ClassII director.

(2) Ordinary resolution: to re-elect Michael Goller to serve as a ClassII director until the 2021 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal:

VotesFor

VotesAgainst

Abstentions

BrokerNon-Votes

616,844,182

7,331,948

196,664

Accordingly, Michael Goller was re-elected to serve as a ClassII director.

(3) Ordinary resolution: to re-elect Thomas Malley to serve as a ClassII director until the 2021 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal:

VotesFor

VotesAgainst

Abstentions

BrokerNon-Votes

623,728,839

447,291

196,664

Accordingly, Thomas Malley was re-elected to serve as a ClassII director.

The proposals for the election of directors related solely to the election of ClassII directors nominated by the Board of Directors. The terms of the following directors continued after the meeting: Ranjeev Krishana, Xiaodong Wang, Qingqing Yi, Timothy Chen, John V. Oyler and Jing-Shyh (Sam) Su.

(4) Ordinary resolution: to approve the BeiGene,Ltd. 2018 Employee Share Purchase Plan:

VotesFor

VotesAgainst

Abstentions

BrokerNon-Votes

589,285,638

35,014,603

72,553

Accordingly, the BeiGene,Ltd. 2018 Employee Share Purchase Plan was approved.

(5) Ordinary resolution: to ratify the appointment of Ernst& Young Hua MingLLP as the Company’s independent registered public accounting firm for the year ending December31, 2018:

VotesFor

VotesAgainst

Abstentions

BrokerNon-Votes

624,173,972

3,523

195,299

Accordingly, the appointment of Ernst& Young Hua Ming LLP as the Company’s independent registered public accounting firm was ratified.

(6) Ordinary resolution: to approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement:

VotesFor

VotesAgainst

Abstentions

BrokerNon-Votes

603,848,147

20,319,455

205,192

Accordingly, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, was approved.

(7) Ordinary resolution: to hold an advisory vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers:

1Year

2Years

3Years

Abstentions

BrokerNon-Votes

621,616,816

1,170,078

226,096

1,359,804

In light of such vote, the Board of Directors has determined that the Company will hold future non-binding advisory votes on executive compensation on an annual basis until the next required vote on the frequency of shareholder votes on the compensation of the Company’s executives.

Item 8.01Other Events.

Adoption of the BeiGene,Ltd. 2018 Inducement Equity Plan

On June6, 2018, the Company adopted the BeiGene,Ltd. 2018 Inducement Equity Plan (the “Inducement Plan”) and reserved 12,000,000 ordinary shares to be used exclusively for grants of awards to individuals that were not previously employees of the Company or its subsidiaries, as a material inducement to the individual’s entry into employment with the Company or its subsidiaries within the meaning of Rule5635(c)(4)of the NASDAQ Listing Rules. The Inducement Plan was approved by the Board of Directors upon recommendation of the Compensation Committee, without shareholder approval to Rule5635(c)(4).The terms and conditions of the Inducement Plan, and the forms of award agreements to be used thereunder, are substantially similar to the Company’s shareholder-approved 2016 Share Option and Incentive Plan, as amended (the “2016 Plan”), and forms of award agreements thereunder.

A complete copy of the Inducement Plan and the forms of Non-Qualified Share Option Agreement and Restricted Share Unit Award Agreement to be used thereunder are filed herewith as Exhibits 10.2, 10.3 and 10.4, respectively, and are incorporated herein by reference. The above summary of the terms of the Inducement Plan and plan documents does not purport to be complete and is qualified in its entirety by reference to such exhibits.

Adoption of Amended Independent Director Compensation Policy

On June6, 2018, upon recommendation of the Compensation Committee, the Board of Directors of the Company approved amendments to the Company’s Independent Director Compensation Policy (the “Director Compensation Policy”). Under the amended Director Compensation Policy, independent directors will be paid an annual cash retainer of $50,000 and additional fees for service as a member or chair of each committee of the Board of Directors on which they serve, ranging from $5,000 to $22,500 per year, as specified in the policy. Additionally, independent directors will be granted equity awards valued at $300,000 in connection with their initial election or appointment to the Board of Directors, pro-rated in the first year of service, and annual equity awards valued at $300,000 on the date of each annual meeting of shareholders. Each of the awards will consist of one-half stock options and one-half restricted share units (“RSUs”), vesting on the earlier of the first anniversary of date of grant or the date of the next annual meeting of shareholders, and in full upon death, disability or the occurrence of specified events in connection with a change of control of the Company. The options will have an exercise price equal to the fair market value of the Company’s ordinary shares on the date of grant, and both the options and RSUs will be granted under the 2016 Plan and forms of award agreements thereunder. In addition, under the terms of the 2016 Plan, the value of all equity awards and other cash compensation paid to each independent director for their service as an independent director may not exceed $500,000 in any calendar year. A complete copy of the Director Compensation Policy, as amended, the revised form of Non-Qualified Share Option Agreement for Non-Employee Directors and the revised form of Restricted Share Unit Award Agreement for Non-Employee Directors are filed herewith as Exhibits 10.5, 10.6 and 10.7, respectively, and are incorporated herein by reference. The above summary of the terms of the Director Compensation Policy and form agreements to be used in connection therewith does not purport to be complete and is qualified in its entirety by reference to such exhibits.

Item 9.01Financial Statements and Exhibits

(d)Exhibits.

ExhibitNo.

Description

10.1

BeiGene,Ltd. 2018 Employee Share Purchase Plan

10.2

BeiGene,Ltd. 2018 Inducement Equity Plan

10.3

Formof Non-Qualified Share Option Agreement under the BeiGene,Ltd. 2018 Inducement Equity Plan

10.4

Formof Restricted Share Unit Award Agreement under the BeiGene,Ltd. 2018 Inducement Equity Plan

10.5

BeiGene,Ltd. Independent Director Compensation Policy, as amended

10.6

Formof Non-Qualified Share Option Agreement for Non-Employee Directors under the BeiGene,Ltd. 2016 Share Option and Incentive Plan

10.7

Formof Restricted Share Unit Award Agreement for Non-Employee Directors under the BeiGene,Ltd. 2016 Share Option and Incentive Plan

***


BeiGene, Ltd. Exhibit
EX-10.1 2 a18-14700_2ex10d1.htm EX-10.1 Exhibit 10.1   BEIGENE,…
To view the full exhibit click here

About BEIGENE,LTD. (NASDAQ:BGNE)

BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers.